Investors expect the company to underperform the broader industry, reflecting in its low P/S ratio. Limited growth rates are anticipated to persist, reducing stock value. If medium-term revenue trends persist, a share price reversal seems unlikely.

Concerns rise for COFCO Biotechnology's financial performance and competitiveness due to decreasing ROCE and sales. Responding to these trends, the stock fell by 11% over five years. Alternatives should be considered unless positive changes occur.